ESK 1

Drug Profile

ESK 1

Alternative Names: ESK1 monoclonal antibody - Eureka Therapeutics/Memorial Sloan Kettering Cancer Center; ESKM; Fc-enhanced TCR-like antibody - Novartis; Intracellular WT 1 targeting anticancer therapeutics - Novartis

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eureka Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Monoclonal antibodies
  • Mechanism of Action Intracellular signalling peptide and protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leukaemia; Mesothelioma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 20 Jul 2018 ESK 1 is still in preclinical trials for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy) in USA (Parenteral) (Eureka Pipeline July 2018)
  • 20 Jul 2018 ESK 1 is still in preclinical trials for Mesothelioma in USA (Parenteral) (Eureka Pipeline July 2018)
  • 20 Jul 2018 ESK 1 is still in preclinical trials for Leukaemia in USA (Parenteral) (Eureka Pipeline July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top